<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818140</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004770-16</org_study_id>
    <nct_id>NCT02818140</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Transmuscular Quadratus Lumborum Block for Percutaneous Nephrolithotomy</brief_title>
  <official_title>Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Percutaneous Nephrolithotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing percutaneous nephrolithotomy (PNL) suffer from acute postoperative pain,
      despite a multimodal analgesic regime.

      We hypothesize that active (ropivacaine) transmuscular quadratus lumborum (TQL) block will
      significantly reduce postoperative opioid consumption and pain following PNL operation
      compared with placebo (saline) TQL block.

      The aim of this study is to investigate the effect of ultrasound-guided (USG) TQL block
      concurrent with a multimodal analgesic regime compared to the multimodal analgesic regime
      alone (and placebo TQL block) in a randomized and placebo controlled design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing percutaneous nephrolithotomy (PNL) suffer from acute postoperative pain,
      despite a multimodal analgesic regime, and the patients receive considerable amounts of long
      lasting opioids. For the patients this greatly increase the risk of experiencing the adverse
      effects of opioids.

      The ultrasound-guided (USG) transmuscular quadratus lumborum (TQL) block is a single dosage
      of local anesthetic (LA) delivered in the plane between the psoas major muscle and the
      quadratus lumborum muscle. LA spreads cephalad into the thoracic paravertebral space to reach
      the somatic ventral rami (intercostal nerves) and the thoracic sympathetic trunk. The TQL
      block can reduce visceral pain and pain originating from the abdominal wall and has an
      expected duration of analgesic efficacy of 24 hours.

      The aim of this study is to investigate the efficacy of the active USG TQL block together
      with the multimodal analgesic regime to reduce postoperative opioid consumption and pain
      compared to placebo USG TQL block and the multimodal analgesic regime in a randomized and
      placebo controlled design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Morphine consumption in the first 6 hours postoperatively - data from PCA pump and patient medical record</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>15 min, 30 min, 1 h, 2h, 4h, 6h, 12h, 18h, 24 hours postoperatively</time_frame>
    <description>Data from PCA pump and patient electronic file</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score at rest (NRS 0-10/10)</measure>
    <time_frame>15 min, 30 min, 1 h, 2h, 4h, 6h, 12h, 18h, 24 hours postoperatively</time_frame>
    <description>Pain score NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score at sitting position (NRS 0-10/10)</measure>
    <time_frame>15 min, 30 min, 1 h, 2h, 4h, 6h, 12h, 18h, 24 hours postoperatively</time_frame>
    <description>Pain score NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ambulation - get out of bed</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Time to first ambulation from bed to walk on the floor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid side effects (nausea, vomiting)</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>PONV, number of episodes, antiemetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS score during application of the TQL block (NRS 0-10/10)</measure>
    <time_frame>intraoperative</time_frame>
    <description>Procedure discomfort</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Ropivacaine TQL block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unilateral single shot ultrasound-guided TQL block with 30 ml of ropivacaine 0.75%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo TQL block</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Unilateral single shot ultrasound-guided TQL block with 30 ml saline 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ropivacaine TQL block</intervention_name>
    <description>Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure</description>
    <arm_group_label>Ropivacaine TQL block</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Saline TQL block</intervention_name>
    <description>Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure</description>
    <arm_group_label>Placebo TQL block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>Ropivacaine TQL block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Placebo TQL block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <arm_group_label>Ropivacaine TQL block</arm_group_label>
    <arm_group_label>Placebo TQL block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Scheduled for elective PNL operation in general anaesthesia with propofol and remifentanil.

        Received oral and written information about the trial Signed the informed consent American
        Society of Anesthesiologists (ASA) classification 1-3

        Exclusion Criteria:

        Cannot cooperate Does not speak or understand Danish Allergy towards drugs used in the
        trial Large daily consumption of opioids Known alcohol or drug abuse Difficulty or
        inability to visualize the relevant muscular or fascial structures necessary to perform the
        USG-TQL block Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette Dam, MD, PhD Fellow</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Hansen CK, Dam M, Bendtsen TF, Børglum J. Ultrasound-Guided Quadratus Lumborum Blocks: Definition of the Clinical Relevant Endpoint of Injection and the Safest Approach. A A Case Rep. 2016 Jan 15;6(2):39. doi: 10.1213/XAA.0000000000000270.</citation>
    <PMID>26771297</PMID>
  </reference>
  <reference>
    <citation>Dam M, Hansen CK, Børglum J, Chan V, Bendtsen TF. A transverse oblique approach to the transmuscular Quadratus Lumborum block. Anaesthesia. 2016 May;71(5):603-4. doi: 10.1111/anae.13453.</citation>
    <PMID>27072772</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Transmuscular quadratus lumborum block</keyword>
  <keyword>Block</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>TQL</keyword>
  <keyword>percutaneous nephrolithotomy</keyword>
  <keyword>PNL</keyword>
  <keyword>Ultrasound-guided</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

